CME Presentations

Outcomes in Spinal Muscular Atrophy


Presentations


Speakers

  • Vanessa Battista, MS, RN, CPNP

    Vanessa Battista, MS, RN, CPNP

    Vanessa Battista, MS, RN, CPNP

    Nurse Practitioner, Neuromuscular Program

    Vanessa Battista, MS, RN, CPNP-PC, is a board-certified pediatric nurse practitioner and a member of the neuromuscular team at The Children’s Hospital of Philadelphia. She teaches at the local, national, and international level, and is a member of the ELNEC pediatric faculty, for which she was the recipient of the Award for Excellence. Ms Battista is an active reviewer for publications and has authored several book chapters and articles on various aspects of pediatric palliative care and neuromuscular disease. She serves as a board member for organizations that provide services for patients and families living with life-threatening diseases. Ms Battista is currently obtaining her Master of Business Administration and Executive Doctor of Nursing Practice from Johns Hopkins University.
  • Basil T. Darras, MD

    Basil T. Darras, MD

    Basil T. Darras, MD

    Joseph J. Volpe Professor of Neurology

    Basil T. Darras, MD, is the Joseph J. Volpe Professor of Neurology at Harvard Medical School, and associate neurologist-in-chief, chief of the Division of Clinical Neurology, and director of the neuromuscular program at Boston Children’s Hospital. His primary research focus is on pediatric neuromuscular disorders, specifically molecular genetics, diagnostics, and therapeutics of many myopathies, including spinal muscular atrophy (SMA), which has resulted in over 190 original reports in peer-reviewed journals and over 80 chapters, reviews, and editorials. Additionally, he receives frequent invitations to lecture both nationally and internationally. Dr Darras is editor in chief for the second edition of Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician’s Approach.

CME Information

Spinal Muscular Atrophy: Best Practices in Diagnosis and Management


Einstein LogoMontefiore Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Summarize clinical practice/consensus guidelines for the comprehensive management of spinal muscular atrophy (SMA)
  • Determine strategies to incorporate new disease-modifying therapies for SMA into daily clinical practice
Presented by the Albert Einstein College of Medicine and Montefiore Medical Center in Joint Providership with PlatformQ Health Education, LLC

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Biogen.

TUITION

Complimentary

ACCREDITATION STATEMENT

The activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and PlatformQ Health Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS

Live Internet Activity
Albert Einstein College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material
Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS

The American Academy of Nurse Practitioners (AANP) and American Nurses Credentialing Center (ANCC) accept AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

DATE OF RELEASE/EXPIRATION

Live Internet Activity
December 12, 2019 from 2:30 PM EST – 3:30 PM EST

Enduring Material
The enduring material will be available from December 12, 2019 to December 12, 2020.

INTENDED AUDIENCE

This activity is intended for pediatric neurologists, neurologists, pediatricians, primary care physicians, internal medicine physicians, nurse practitioners, physician assistants, physical therapists, occupational therapists, and other health care professionals interested and/or involved with the management of patients with SMA.

ESTIMATED TIME TO COMPLETE

This activity consists of one session which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

HARDWARE / SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenter Disclosures
Basil T. Darras, MD Consulting Fee: Biogen, Roche, Cytokinetics, Sarepta, Avexis
Contracted Research: grants from, Ionis Pharmaceuticals, Inc. and Biogen during ENDEAR, CHERISH, CS2, CS12, CS11 studies, AveXis Biotechnology, Cytokinetics, Fibrogen, PTC Therapeutics, Roche, Santhera Therapeutics, Sarepta Therapeutics, and Summit Therapeutics; Dr. Darras reports no personal financial interests in these companies.
Vanessa Battista, MS, RN, CPNP Consulting Fee: AveXis Biotechnology Advisory Board
Speakers Bureau: AveXis Biotechnology
Danyelle Sun, MSW Consulting Fee: Genentech
Rachael Brown Has nothing to disclose relevant to this activity.
Patrick Brown Has nothing to disclose relevant to this activity.
Peer Reviewer Disclosures
David Kaufman, MD Has nothing to disclose relevant to this activity.
Joint Provider
PlatformQ Health Education, LLC Disclosures
Anne Roc, Medical Director Has nothing to disclose relevant to this activity.
Elizabeth del Nido, Program Manager Has nothing to disclose relevant to this activity.

CONTACT INFORMATION

Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, please contact NeuroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.

DISCLAIMERS (if applicable)

The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine, NeuroSeriesLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.